Nipocalimab Granted U.S. FDA Priority Review for the Treatment of Generalized Myasthenia Gravis
Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad population of antibody positive adult patients:… Read More